Graphite Granules 4x 4 X Tablet is a Health Canada–registered human drug (DIN 00767581) held by Homeocan Inc., containing Graphite. Health Canada lists its status as Cancelled Post Market (status date 14 Oct 1997). Nexara Health has matched 15 registrations of Graphite across 4 other regulated markets.
Health Canada registration
| DIN | 00767581 |
|---|---|
| Brand name | Graphite Granules 4x |
| Active ingredient | Graphite |
| Strength | 4 X |
| Dosage form | Tablet |
| Route | Oral |
| Company | Homeocan Inc. |
| Status | Cancelled Post Market — 14 Oct 1997 |
| Class | Human |
| ATC | |
| AHFS | 92:02.00* ; See footnote |
| Regulator record | Health Canada DPD entry · Product monograph |
Graphite registered in other markets
15 registrations of the same molecule in 4 national registries outside Canada (first 11 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| Czech Republic | Pulfunvu | — | Rad Kit | R | SUKL DLP | |
| Poland | RespiriScint | Cyclomedica Ireland Limited | 1,34 g | Zestaw do sporządzania preparatu radiofarmaceutycznego | 2030-05-12 | URPL RPL |
| United Arab Emirates | Graphites - Boiron | BOIRON, France, Messimy | 1 DH - 200 CH | Pillules | Active | EDE |
| United States | Graphites | Boiron | Pellet | listed | FDA NDC | |
| United States | Graphites | Boiron | Pellet | listed | FDA NDC | |
| United States | Graphites | Boiron | Pellet | listed | FDA NDC | |
| United States | Graphites | Boiron | Pellet | listed | FDA NDC | |
| United States | Graphites | Boiron | Pellet | listed | FDA NDC | |
| United States | Graphites | Boiron | Pellet | listed | FDA NDC | |
| United States | Graphites | Boiron | Pellet | listed | FDA NDC | |
| United States | Graphites | Boiron | Pellet | listed | FDA NDC |
See every manufacturer of Graphite worldwide →
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Graphite Granules 4x (DIN 00767581) marketed in Canada?
No. Health Canada lists DIN 00767581 as Cancelled Post Market as of 14 Oct 1997.
Who holds the Canadian licence for this product?
Homeocan Inc. is the company of record in the Health Canada Drug Product Database.
Is Graphite registered outside Canada?
Yes — Nexara Health has matched 15 registrations in 4 other markets (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 00767581, status date 1997-10-14; national medicine registries: EDE, FDA NDC, SUKL DLP, URPL RPL. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 00767581, status date 1997-10-14; national medicine registries: EDE, FDA NDC, SUKL DLP, URPL RPL.
Health Canada Drug Product Database (DPD), DIN 00767581, status date 1997-10-14; national medicine registries: EDE, FDA NDC, SUKL DLP, URPL RPL. Last reviewed 2026-09-17. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.